Tags

Type your tag names separated by a space and hit enter

Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
Br J Ophthalmol. 2021 Mar 19 [Online ahead of print]BJ

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD.

Authors+Show Affiliations

Institute of Ophthalmology, University College London, London, London, UK. Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.Institute of Ophthalmology, University College London, London, London, UK. Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.Institute of Ophthalmology, University College London, London, London, UK. Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.Institute of Ophthalmology, University College London, London, London, UK michel.michaelides@ucl.ac.uk. Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33741584

Citation

Cabral de Guimaraes, Thales Antonio, et al. "Treatments for Dry Age-related Macular Degeneration: Therapeutic Avenues, Clinical Trials and Future Directions." The British Journal of Ophthalmology, 2021.
Cabral de Guimaraes TA, Daich Varela M, Georgiou M, et al. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol. 2021.
Cabral de Guimaraes, T. A., Daich Varela, M., Georgiou, M., & Michaelides, M. (2021). Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. The British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2020-318452
Cabral de Guimaraes TA, et al. Treatments for Dry Age-related Macular Degeneration: Therapeutic Avenues, Clinical Trials and Future Directions. Br J Ophthalmol. 2021 Mar 19; PubMed PMID: 33741584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. AU - Cabral de Guimaraes,Thales Antonio, AU - Daich Varela,Malena, AU - Georgiou,Michalis, AU - Michaelides,Michel, Y1 - 2021/03/19/ PY - 2020/11/19/received PY - 2021/01/20/revised PY - 2021/02/23/accepted PY - 2021/3/20/entrez PY - 2021/3/21/pubmed PY - 2021/3/21/medline KW - angiogenesis KW - degeneration KW - genetics KW - macula KW - retina JF - The British journal of ophthalmology JO - Br J Ophthalmol N2 - Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD. SN - 1468-2079 UR - https://www.unboundmedicine.com/medline/citation/33741584/Treatments_for_dry_age_related_macular_degeneration:_therapeutic_avenues_clinical_trials_and_future_directions_ L2 - http://bjo.bmj.com/lookup/pmidlookup?view=long&pmid=33741584 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.